Literatuurlijst Farmacotherapie acute episoden

• Ahuja, S., Bose, A., Lu, K., Greenberg, W., Németh, G., & Laszlovszky, I. (2011, October). A multicenter, randomized, double-blind trial to evaluate the effect of cariprazine in bipolar depression. In: A. Leon, & V. Haynes (Chairs), Conference of the International Society for CNS Clinical Trials and Methodology. Amelia Island, Florida: ISCTM.
• Altshuler, L., Suppes, T., Black, D., Nolen, W.A., Keck, P.E., Frye, M.A., e.a. (2004). Impact of antidepressant discontinuation after acture bipolar depression remission on rates of depressive relapse at 1-year follow-up. American Journal of Psychiatry, 160, 1252-1262.
• Amsterdam, J.D., & Shults, J. (2005). Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression: Lack of manic induction. Journal of Affective Disorders, 87, 121-130.
• Amsterdam, J.D., & Shults, J. (2009). Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode? Journal of Affective Disorders, 115, 234-240.
• Astrazeneca (2011b). An 8-week, multicenter, double-blind, randomized, parallel-group, placebo-controlled study of the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release in children and adolescent subjects with bipolar depression. Available from: clinicaltrials.gov/show/ NCT00811473 [accessed 17 February 2014].
• Astrazeneca (2011b). An international, multicenter, double-blind, randomized, placebo-controlled, phase iv study of the safety and efficacy of lithium versus placebo as an add on to SEROQUEL XR (quetiapine fumarate) in adult patients with acute mania. [NCT00931723/D144AC00003]. Available from: http://clinicaltrials.gov/show/NCT00931723 [accessed February 28 2014].
• Astrazeneca (2012a). Effectiveness of quetiapine XR vs. sertaline in acute bipolar depression as add-on therapy to previous mood stabilizer treatment: a pilot study [D1443L00058].
• Astrazeneca (2012b). Efficacy and safety of quetiapine versus quetiapine plus lithium in bipolar depression (QUALITY) [D1443L00055]. Available from: https://clinicaltrials.gov/ct2/show/NCT00883493 [accessed 27 March 2013].
• Baldessarini, R.J., Faedda, G.L., Offidani, E., Vazquez, G.H., Marangoni, C., Serra, G., e.a. (2013). Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. Journal of Affective Disorders, 148, 129-135.
• Bauer, M.S., & Whybrow, P.C. (1990). Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Archives of General Psychiatry, 47, 435-440.
• Bauer, M., Beaulieu, S., Dunner, D.L., Lafer, B., & Kupka, R. (2008). Rapid cycling bipolar disorder: diagnostic concepts. Bipolar Disorders, 10, 153-162.
• Behzadi, A.H., Omrani, Z., Chalian, M., Asadi, S., & Ghadiri, M. (2009). Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatrica Scandinavica, 120, 441-445.
• Bloch, M.H., & Hannestad, J. (2012). Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychaitry, 17, 1272-1282.
• Bose, A., Starace, A., Wang, Q., Diaz, E., Goodman, J., Ruth, A., e.a. (2012, May). Cariprazine in the treatment of acute mania in bipolar disorder: A doubleblind, placebo-controlled, phase III trial. In: M.D. Silk (Chair), 165th Annual Meeting of the American Psychiatric Association. Philadelphia, PA: APA.
• Bowden, C.L., Mitchell, P., & Suppes, T. (1999). Lamotrigine in the treatment of bipolar depression. European Neuropsychopharmacology, 9, S113-S17.
• Brazier, J., Ratcliffe, J., Salomon, J., & Tsuchiya, A. (2007). Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press.
• Bridle, C., Palmer, S., Bagnall, A.M., Darba, J., Duffy, S., Sculpher, M., e.a. (2004). A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technology Assessment, 8, iii-iv, 1-187.
• Briggs, A., Sculpher, M., & Claxton, K. (2006). Decision modelling for health economic evaluation. New York: Oxford University Press.
• Bristol-Myers Squibb (2006). A multicenter, randomized, double-blind, placebocontrolled study of aripiprazole in the treatment of patients with bipolar I disorder with a major depressive episode [CN138096].
• Bristol-Myers Squibb (2007). A multicenter, randomized, double-blind, placebocontrolled study of aripiprazole in the treatment of patients with bipolar I disorder with a major depressive episode [CN138146].
• Bristol-Myers Squibb (2011). A 12-week, multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of adjunctive aripiprazole therapy in the treatment of mania in bipolar I disorder patients treated with valproate or lithium and in need of further clinical improvement.
• Brown, E., Dunner, D.L., McElroy, S.L., Keck, P.E., Adams, D.H., Degenhardt, E., e.a. (2009). Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. International Journal of Neuropsychopharmacology, 12, 773-782.
• Brown, E.B., McElroy, S.L., Keck, P.E., Jr., Deldar, A., Adams, D.H., Tohen, M., e.a. (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. Journal of Clinical Psychiatry, 67, 1025-1033.
• Calabrese, J.R., Bowden, C.L., Sachs, G.S., Ascher, J.A., Monaghan, E., & Rudd, G.D. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry, 60, 79-88.
• Calabrese, J.R., Huffman, R.F., White, R.L., Edwards, S., Thompson, T.R., Ascher, J.A., e.a. (2008). Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders, 10, 323-333.
• Calabrese, J.R., Keck, P.E. Jr., Macfadden, W., Minkwitz, M., Ketter, T.A., Weisler, R.H., e.a. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry, 162, 1351-1360.
• Caldwell, D.M., Ades, A.E., & Higgins, J.P. (2005). Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ, 331, 897-900.
• Camuri, G., Dell’Osso, B., Guerrieri, I., Arici, C., Oldani, L., & Altamura, A.C. (2013). Augmentative repetitive transcranial magnetic stimulation (RTMS) in the acute treatment of drug-resistant depression [Abstracts of the 21th European Congress of Psychiatry]. European Psychiatry, 28(Supplement), 1794.
• Caro, J.J., Huybrechts, K.F., Xenakis, J.G., O’Brien, J.A., Rajagopalan, K., & Lee, K. (2006). Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials. Current Medical Research and Opinion, 22, 2233-2242.
• Carvalho, A.F., Dimellis, D., Gonda, X., Vieta, E., Mclntyre, R.S., & Fountoulakis, K.N. (2014). Rapid cycling in bipolar disorder: a systematic review. Journal of Clinical Psychiatry, 75, e578-586.
• Chalon, S. (2006). Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins, Leukotrienes and Essential Fatty Acids, 75, 259-269.
• Cheema, N., Frangou, S., & McCrone, P. (2013). Cost-effectiveness of ethyleicosapentaenoic acid in the treatment of bipolar disorder. Therapeutic Advances in Psychopharmacology, 3, 73-81.
• Chengappa, K.N., Levine, J., Gershon, S., Mallinger, A.G., Hardan, A., Vagnucci, A., e.a. (2000). Inositol as an add-on treatment for bipolar depression. Bipolar Disorders, 2, 47-55.
• Chiu, C.C., Huang, S.Y., Chen, C.C., & Su, K.P. (2005). Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. Journal of Clinical Psychiatry, 66, 1613-1614.
• Christensen, J., Gronborg, T.K., Sorensen, M.J., Schendel, D., Parner, E.T., Pedersen, L.H., e.a. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA, 309, 1696-1703.
• Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., e.a. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet, 378, 1306-1315.
• Cipriani, A., Hawton, K., Stockton, S., & Geddes, J.R. (2013). Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ, 346, f3646.
• Citrome, L., Ketter, T.A., Cucchiaro, J., & Loebel, A. (2014). Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 155, 20-27.
• Collins, J.C., & McFarland, B.H. (2008). Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. Journal of Affective Disorders, 107, 23-28.
• Colombo, C., Lucca, A., Benedetti, F., Barbini, B., Campori, E., & Smeraldi E. (2000). Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: Replication of main effects and interaction. Psychiatry Research, 95, 43-53.
• Cookson, J., Keck, P.E. Jr., Ketter, T.A., & Macfadden, W. (2007). Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. International Clinical Psychopharmacology, 22, 93-100.
• Corya, S.A., Perlis, R.H., Keck, P.E. Jr., Lin, D.Y., Case, M.G., Williamson, D.J. e.a. (2006). A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. Journal of Clinical Psychiatry, 67, 798-806.
• Curtis, L. (2013). Unit costs of health and Social care 2013. Canterbury: University of Kent.
• Dauphinais, D.R., Rosenthal, J.Z., Terman, M., DiFebo, H.M., Tuggle, C., & Rosenthal, N.E. (2012). Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression. Psychiatry Research, 196, 57-61.
• Davis, L.L., Bartolucci, A., & Petty, F. (2005). Divalproex in the treatment of bipolar depression: a placebo-controlled study. Journal of Affective Disorders, 85, 259-266.
• Denicoff, K.D., Singh, J., Sporn, J., Zarate, C.A., Quiroz, J.A., Brutsche, N.E., e.a. (2005). Antiglucocorticoid therapy in bipolar depression with mifepristone. Bipolar Disorders, 75(Suppl 2), 47.
• Dennehy, E.B., Schnyer, R., Bernstein, I.H., Gonzalez, R., Shivakumar, G., Kelly, D.I., e.a. (2009). The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for acute symptoms in bipolar disorder. Journal of Clinical Psychiatry, 70, 897-905.
• Depp, C.A.D. (2006). Health-related quality of life and functioning of middleaged and elderly adults with bipolar disorder. Journal of Clinical Psychiatry, 67, 215-221.
• Dias, S., Sutton, A.J., Ades, A.E., & Welton, N.J. (2013). Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Medical  Decision Making, 33, 607-617.
• Diazgranados, N., Ibrahim, L., Brutsche, N.E., Newberg, A., Kronstein, P., Khalife, S., e.a. (2010). A randomized add-on trial of an n-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry, 67, 793-802.
• Dolan, P., Gudex, C., Kind, P., & Williams, A. (1996). The time trade-off method: results from a general population study. Health Economics, 5, 141-154.
• Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35, 1095-1108.
• Dolberg, O.T., Schreiber, S., & Grunhaus, L. (2001). Transcranial magnetic stimulation-induced switch into mania: a report of two cases. Biological Psychiatry, 49, 468-470.
• Dube, S., Tollefson, G.D., Thase, M.E., Briggs, S.D., Campen, L.E. van, Case, M., e.a. (2007). Onset of antidepressant effect of olanzapine and olanzapine/ fluoxetine combination in bipolar depression. Bipolar Disorders, 9, 618-627.
• Ekman, M., Lindgren, P., Miltenburger, C., Meier, G., Locklear, J.C., & Chatterton, M.L. (2012). Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. PharmacoEconomics, 30, 513-530.
• Endicott, J., Paulsson, B., Gustafsson, U., Schioler, H., & Hassan, M. (2008). Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. Journal of Affective Disorders, 111, 306-319.
• Endicott, J., Rajagopalan, K., Minkwitz, M., Macfadden, W.; BOLDER Study Group. (2007). A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. International Clinical Psychopharmacology, 22, 29-37.
• Fenwick, E., Claxton, K., & Sculpher, M. (2001). Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics, 10, 779-787.
• Fieve, R.R., Platman, S.R., & Plutchik, R.R. (1968). The use of lithium in affective disorders I: Acute endogenous depression. American Journal of Psychiatry, 125, 487-491.
• Forest (2010). Forest Laboratories, Inc Forest Laboratories, Inc. and Gedeon Richter Plc Announce results from a phase II study of cariprazine for the treatment of bipolar depression. Avaiable from: http://news.frx.com/pressrelease/rd-news/forest-laboratories-inc-and-gedeon-richter-announcepositive-phase-iii-results [accessed 20 February 2014].
• Forest (2012). Forest Laboratories, Inc. and Gedeon Richter Plc announce positive phase III results with the investigational antipsychotic cariprazine in patients with acute mania associated with bipolar I disorder [Press release 8 February 2012]. Available from: http://news.frx.com/press-release/productnews/forest-laboratories-inc-and-gedeon-richter-plc-announce-positivephase-ii [accessed 20 February 2014].
• Fountoulakis, K.N., Kontis, D., Gonda, X., & Yatham, L.N. (2013). A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disorders, 15, 115-1137.
• Frangou, S., Lewis, M., & McCrone, P. (2006). Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. British Journal of Psychiatry, 188, 46-50.
• Furey, M.L., & Zarate, C.A. (2013). Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects. Journal of Clinical Psychiatry, 74, 850-851.
• Gao, K., Pappadopulos, E., Karayal, O.N., Kolluri, S., & Calabrese, J.R. (2013). Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. Journal of Clinical Psychopharmacology, 33, 425-431.
• Gao, K.M., Kemp, D.E., Ganocy, S.J., Muzina, D.J., Xia, G.H., Findling, R.L., e.a. (2008). Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disorders, 10, 907-915.
• Geddes, J.R., Calabrese, J.R., & Goodwin, G.M. (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry, 194, 4-9.
• Ghaemi, S.N., El-Mallakh, R.S., Baldassano, C.F., Ostacher, M.M., Hsu, D.J., Pardo, T.B., e.a. (2005). A randomized clinical trial of efficacy and safety  of long-term antidepressant use in bipolar disorder [abstract]. Bipolar Disorders, 7(Suppl 2), 59.
• Ghaemi, S.N., Gilmer, W.S., Goldberg, J.F., Zablotsky, B., Kemp, D.E., Kelley, M.E., e.a. (2007). Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Journal of Clinical Psychiatry, 68, 1840-1844.
• Gijsman, H.J., Geddes, J.R., Rendell, J.M., Nolen, W.A., & Goodwin, G.M. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry, 161, 1537-15347.
• Gitlin, M., & Frye, M.A. (2012). Maintenance therapies in bipolar disorders. Bipolar Disorders, 14(Suppl 2), 51-65.
• GlaxoSmithKline (2005a). A 52 week, open-label, multicenter, flexible-dose continuation study of lamictal (lamotrigine) in patients with bipolar disorder [SCAB2002]. Available from: http://www.gsk-clinicalstudyregister.com/ study/SCAB2002#rs [accessed 28 February 2014].
• GlaxoSmithKline (2005b). A 52 week, open, multicenter, flexible-dose continuation study of lamictal (lamotrigine) in patients with bipolar disorder who have completed protocol [SCAA2010]. Available from: http://www.gskclinicalstudyregister.com/study/SCAA2014#rs [accessed 28 February 2014].
• GlaxoSmithKline (2005c). A double-blind, placebo-controlled, comparison of imipramine and paroxetine in the treatment of bipolar depression [29060/352]. Available from: http://www.gsk-clinicalstudyregister.com/ study/29060/352#rs [accessed 28 February 2014].
• GlaxoSmithKline (2005d). A multicenter, double-blind, placebo-controlled, fixed dose (50 or 200mg per day) 7 week evaluation of the safety and efficacy of lamictal (lamotrigine) in the treatment of a major depressive episode in patients suffering from bipolar disorder [SCAB2001]. Available from: http://www.gsk-clinicalstudyregister.com/study/SCAB2001#rs [accessed 28 February 2014].
• GlaxoSmithKline (2005e). A multicenter, double-blind, placebo-controlled, flexible dose (100-400mg) 10 week evaluationof the safety and efficacy of lamictal (lamotrigine) in the treatment of a major depressive episode in patients with bipolar disorder [SCAA2010]. Available from: http://www. gsk-clinicalstudyregister.com/study/SCAA2010#rs [accessed 28 February 2014].
• Glover, G., Arts, G., & Babu, K.S. (2006). Crisis resolution/home treatment teams and psychiatric admission rates in England. British Journal of Psychiatry, 189, 441-445.
• Goldberg, J.F., Burdick, K.E., & Endick, C.J. (2004). Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. American Journal of Psychiatry, 161, 564-566.
• Goldsmith, D.R., Wagstaff, A.J., Ibbotson, T., & Perry, C.M. (2004). Spotlight on lamotrigine in bipolar disorder. CNS Drugs, 18, 63-67.
• Goodwin, F.K., Fireman, B., Simon, G.E., Hunkeler, E.M., Lee, J., & Revicki, D. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA, 290, 1467-1473.
• Goodwin, G.M. (2007). Quetiapine more effective than placebo for depression in bipolar I and II disorder. Evidence-based Mental Health, 10, 82.
• Grisaru, N., Chudakov, B., Yaroslavsky, Y., & Belmaker, R.H. (1998). Transcranial magnetic stimulation in mania: a controlled study. American Journal of Psychiatry, 155, 1608-1610.
• Grunze, H.C. (2010). Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression. Evidence-based Mental Health, 13, 88.
• Haslemo, T., Olsen, K., Lunde, H., & Molden, E. (2012). Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking. Therapeutic Drug Monitoring, 34, 512-517.
• Hayes, J., Prah, P., Nazareth, I., King, M., Walters, K., Petersen, I., e.a. (2011). Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One, 6, e28725.
• Hayhurst, H.P. (2006). Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures. Quality of Life Research, 15, 1271-1280.
• Health and Social Care Information Centre (2013). Prescription Cost Analysis England 2012: Prescription items dispensed in the community in England and listed alphabetically within chemical entity by therapeutic class. Leeds: Health and Social Care Information Centre.
• Health and Social Care Information Centre (2014). Prescription Cost Analysis England 2013: Prescription items dispensed in the community in England and listed alphabetically within chemical entity by therapeutic class. Leeds: Health and Social Care Information Centre.
• Himmelhoch, J.M., Thase, M.E., Mallinger, A.G., & Houck, P. (1991). Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry, 148, 910-916.
• Hirschfeld, R.M., Weisler, R.H., Raines, S.R., Macfadden, W.; BOLDER Study Group (2006). Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, doubleblind, placebo-controlled study. Journal of Clinical Psychiatry, 67, 355-362.
• Israel, M., & Beaudry, P. (1988). Carbamazepine in psychiatry: a review. Canadian Journal of Psychiatry, 33, 577-584.
• Johnson, S., Nolan, F., Pilling, S., Sandor, A., Hoult, J., McKenzie, N., e.a. (2005). Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study. BMJ, 331, 599.
• Judd, L., Akiskal, H.S., Schettler, P., Coryell, W., Endicott, J., Maser, J.D., e.a. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry, 60, 261-269.
• Judd, L., Akiskal, H.S., Schettler, P., Endicott, J., Maser, J., Solomon, D.A., e.a. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry, 59, 530-537.
• Judd, L.L., Schettler, P.J., Akiskal, H.S., Coryell, W., Leon, A.C., Maser, J.D., e.a. (2008). Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Archives of General Psychiatry, 65, 386-394.
• Kanba, S., Kawasaki, H., Ishigooka, J., Sakamoto, K., Kinoshita, T., & Kuroki, T. (2014). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). World Journal of Biological Psychiatry, 15, 113-121.
• Kaplan, R.M., & Anderson, J.P. (1988). A general health policy model: update and applications. Health Service Research, 23, 203-235.
• Kaptsan, A., Yaroslavsky, Y., Applebaum, J., Belmaker, R.H., & Grisaru, N. (2003). Right prefrontal TMS versus sham treatment of mania: a controlled study. Bipolar Disorders, 5, 36-39.
• Katagiri, H., Tohen, M., McDonnell, D.P., Fujikoshi, S., Case, M., Kanba, S., e.a. (2013). Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry, 13, 138.
• Keck, P.E. Jr., Mintz, J., McElroy, S.L., Freeman, M.P., Suppes, T., Frye, M.A., e.a. (2006). Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biological Psychiatry, 60, 1020-1022.
• Kessell, A., & Holt, N.F. (1975). A controlled study of a tetracyclic antidepressant-maprotiline (Ludiomil). Medical Journal of Australia, 1, 773-776.
• Ketter, T.A., Cucchiaro, J., Silva, R., Warner, P., Pikalov, A., Sarma, K., e.a. (2012). Lurasidone for bipolar i depression: Effects on quality of life and functioning. Neuropsychopharmacology, 38, S169-S170.
• Knesivich, M., Wang, Q., Bose, A., Papadakis, K., Starace, A., Thomson, L., e.a. (2009, June-July). Phase II trial of cariprazine in acute mania associated with bipolar I disorder: effect across symptoms. In 49th Annual New Research Approaches for Mental Health Interventions Meeting, 29 June -2 July 2009. Hollywood, FL.
• Kulkarni, J., Anderson, R., Sheppard, S., Garland, K.A., De Castella, A., & Fitzgerald, P.B. (2005). Anti-estrogen: a potential treatment for women in the manic phase of bipolar affective disorder? Australian and New Zealand Journal of Psychiatry, A53.
• Kulkarni, J., Garland, K.A., Scaffidi, A., Headey, B., Anderson, R., de Castella, A., e.a. (2006). A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology, 31, 543-547.
• Kupka, R.W., Luckenbaugh, D.A., Post, R.M., Leverich, G.S., & Nolen, W.A. (2003). Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. Journal of Clinical Psychiatry, 64, 1483-1494.
• Kupka, R.W., Luckenbaugh, D.A., Post, R.M., Suppes, T., Altshuler, L.L., Keck, P.E. Jr. e.a. (2005). Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. American Journal of Psychiatry, 162, 1273-1280.
• Leibenluft, E., Turner, E.H., Feldman-Naim, S., Schwartz, P.J., Wehr, T.A., & Rosenthal, N.E. (1995). Light therapy in patients with rapid cycling bipolar disorder: preliminary results. Psychopharmacology Bulletin, 31, 705-710.
• Lombardo, I., Sachs, G., Kolluri, S., Kremer, C., & Yang, R. (2012). Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar i depression: Did baseline characteristics impact trial outcome? Journal of Clinical Psychopharmacology, 32, 470-478.
• Loos, M.L. van der, Mulder, P.G., Hartong, E.G., Blom, M.B., Vergouwen, A.C., Keyzer, H.J. de, e.a. (2009). Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 70, 223-231.
• Loos, M.L. van der, Mulder, P., Hartong, E.G., Blom, M.B., Vergouwen, A.C., Noorden, M.S. van, e.a. (2010). Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatrica Scandinavica, 122, 246-254.
• Loos, M.L. van der, Mulder, P., Hartong, E.G., Blom, M.B., Vergouwen, A.C., Noorden, M.S. van, e.a. (2011). Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebocontrolled trial with a novel design. Bipolar Disorders, 13, 111-117.
• Lu, G., & Ades, A.E. (2004). Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine, 23, 3105-3124.
• Marmol, F. (2008). Lithium: bipolar disorder and neurodegenerative diseases. Possible cellular echanisms of the therapeutic effects of lithium. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 1761-1771.
• McCrone, P., Johnson, S., Nolan, F., Pilling, S., Sandor, A., Hoult, J., e.a. (2009). Economic evaluation of a crisis resolution service: a randomised controlled trial. Epidemiologia e Psichiatria Sociale, 18, 54-58.
• McElroy, S., Pikalov, A., Cucchiaro, J., Hsu, J., Kroger, H., Phillips, D., e.a. (2013). Short-and longer-term treatment with lurasidone in patients with bipolar I depression: Effect on metabolic syndrome. Neuropsychopharmacology, 38, S535-S536.
• McElroy, S.L., Weisler, R.H., Chang, W., Olausson, B., Paulsson, B., Brecher, M. e.a. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry, 71, 163-174.
• McElroy, S.L., Winstanley, E.L., Martens, B., Patel, N.C., Mori, N., Moeller, D., e.a. (2011). A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. International Clinical Psychopharmacology, 26, 48-53.
• McElroy, S.L., Zarate, C.A., Cookson, J., Suppes, T., Huffman, R.F., Greene, P. e.a. (2004). A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. Journal of Clinical Psychiatry, 65, 204-210. McKnight, R.F., Adida, M., Budge, K., Stockton, S., Goodwin, G.M., & Geddes, J.R. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379, 721-728.
• Minnai, G.P., Salis, P.G., Oppo, R., Loche, A.P., Scano, F., & Tondo, L. (2011). Effectiveness of maintenance electroconvulsive therapy in rapid-cycling bipolar disorder. Journal of ECT, 27, 123-126.
• Morriss, R., Yang, M., Chopra, A., Bentall, R., Paykel, E., & Scott, J. (2013). Differential effects of depression and mania symptoms on social adjustment: prospective observational study in bipolar disorder. Bipolar Disorders, 15, 80-91.
• Muzina, D.J., Ganocy, S., Khalife, S., e.a. (2008, May). A double-blind, placebocontrolled study of divalproex extended-release in newly diagnosed mood stabilizer naive patients with acute bipolar depression (NR3-028). In: D. Baron (Chair), New Research Abstracts of the 161st Annual Meeting of the American Psychiatric Association. Washington, DC: APA.
• Muzina, D.J., Gao, K., Kemp, D.E., Khalife, S., Ganocy, S.J., Chan, P.K., e.a. (2011). Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 72, 813-819.
• Nahas, Z., Kozel, F.A., Li, X., Anderson, B., & George, M.S. (2003). Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disorders, 5, 40-47.
• Nemeroff, C.B., Evans, D.L., Gyulai, L., Sachs, G.S., Bowden, C.L., Gergel, I.P. e.a. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906-912.
• NHS (2012). Hospital episode statistics: Admitted patient care 2011-12: Summary report 2011-12. London: National Health Service, The Information Centre.
• NHS Business Services Authority PPD (2014). Electronic Drug Tariff for England and Wales, February 2014. Redditch, UK: NHS.
• NHS DoH (2013). NHS Reference Costs 2012-13. London: NHS, Department of Health.
• NICE (2003). The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder. NICE Technology Appaisal 66. London 2003.
• NICE (2005). Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments [CG25]. London: National Institute for Health and Care Excellence.
• NICE (2008). Social value judgements: Principles for the development of NICE guidance. London: National Institute for Health and Care Excellence.
• NICE (2009). Depression in adults: The treatment and management of depression in adults [NICE clinical Guideline 90]. Manchester: National Institute for Health and Clinical Excellence. Available from: www.nice.org.uk/CG90.
• NICE (2011a). Self-harm (longer term management) [CG133]. London: National Institute for Health and Care Excellence.
• NICE (2011b). Service user experience in adult Mental health [CG136]. London: National Institute for Health and Care Excellence.
• NICE (2012). The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://publications.nice.org.uk/ pmg6.
• NICE (2013). Process and methods guides: Guide to the methods of technology appraisal 2013. Available from: http://publications.nice.org.uk/pmg9 [accessed 11 March 2014]. London: National Institute for Health and Care Excellence.
• NICE (2014). Psychosis and schizophrenia in adults [CG178]. London: National Institute for Health and Care Excellence.
• NICE/NCCMH (2006). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Leicester and London: The British Psycholgical Society and The Royal College of Psychiatrists.
• NICE/NCCMH (2014). Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. London: National Institute for Health and Care Excellence.
• Nierenberg, A.A., Ostacher, M.J., Calabrese, J.R., Ketter, T.A., Marangell, L.B., Miklowitz, D.J., e.a. (2006). Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry, 163, 210-216.
• Nierenberg, A.A. (2007). Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine. Evidence-based Mental Health, 10, 12.
• Nolen, W.A., Kupka, R.W., Hellemann, G., Frye, M.A., Altshuler, L.L., Leverich, G.S., e.a. (2007). Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatrica Scandinavica, 115, 360-365.
• Novick, D.M., Swartz, H.A., & Frank, E. (2010). Suicide attempts in bipolar 1 and bipolar 11 disorder; a review and meta-analysis of the evidence. Bipolar Disorders, 12, 1-9.
• Oquendo, M.A., Galfalvy, H.C., Currier, D., Grunebaum, M.F., Sher, L., Sullivan, G.M., e.a. (2011). Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. American Journal of Psychiatry, 168, 1050-1056.
• Osher, Y., Bersudsky, Y., & Belmaker, R.H. (2005). Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. Journal of Clinical Psychiatry, 66, 726-729.
• Pacchiarotti, I., Bond, D.J., Baldessarini, R.J., Nolen, W.A., Grunze, H., Licht, R.W., e.a. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170, 1249-1262.
• Pazzaglia, P.J., Post, R.M., Ketter, T.A., Callahan, A.M., Marangell, L.B., Frye, M.A., e.a. (1998). Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. Journal of Clinical Psychopharmacology, 18, 404-413.
• Pfizer (2009a). A six-week, double-blind, multicenter, placebo-controlled study evaluating the efficacy and safety of flexible doses of oral ziprasidone in outpatients with bipolar I depression [NCT00282464]. Avaiable at: www. clinicaltrials.gov [accessed 20 February 2014].
• Pfizer (2009b). A six-week, randomized, double-blind, multicenter, fixed-flexible dose, placebo-controlled study evaluating the efficacy and safety of oral ziprasidone in outpatients with bipolar I depression [NCT00141271]. Available at: www.clinicaltrials.gov [accessed 20 February 2014].
• Praharaj, S.K., Ram, D. & Arora, M. (2009). Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: a randomized sham controlled study. Journal of Affective Disorders, 117, 146-150.
• Preston, G.A., Marchant, B.K., Reimherr, F.W., Strong, R.E., & Hedges, D.W. (2004). Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. Journal of Affective Disorders, 79, 297-303.
• Quante, A., Zeugmann, S., Luborzewski, A., Schommer, N., Langosch, J., Born, C., e.a. (2010). Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Human Psychopharmacology, 25, 126-132.
• Revicki, .D.A., Hanlon, J., Martin, S., Gyulai, L., Nassir Ghaemi, S., Lynch, F., e.a. (2005). Patient-based utilities for bipolar disorder-related health states. Journal of Affective Disorders, 87, 203-210.
• Revicki, D.A., Paramore, L.C., Sommerville, K.W., Swann, A.C., & Zajecka, J.M. (2003). Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Journal of Clinical Psychiatry, 64, 288-294.
• Rosenberg, G. (2007). The mechanism of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cellular and Molecular Life Sciences, 64, 2090-2103.
• Rudd, D., Ascher, J., Huffman, R., Laurenza, A., Astbury, C., Watson, C., e.a. (1998, November). Lamotrigine: Spectrum of antidepressant activity in bipolar disorder. In 11th European College of Neuropsychopharmacology Congress. European College of Neuropsychopharmacology, Paris.
• Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., e.a. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163, 1905-1917.
• Sachs, G.S., Ice, K.S., Chappell, P.B., Schwartz, J.H., Gurtovaya, O., Vanderburg, D.G., e.a. (2011). Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 72, 1413-1422.
• Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., Marangell, L.B., Wisniewski, S.R., Gyulai, L., e.a. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356, 1711-1722.
• Sarris, J., Mischoulon, D., & Schweitzer, I. (2012). Omega-3 for bipolar disorder: meta-analysis of use in mania and bipolar depression. Journal of Clinical Psychiatry, 73, 81-86.
• Schaffer, L.C., Schaffer, C.B., Miller, A.R., Manley, J.L., Piekut, J.A., & Nordahl, T.E. (2013). An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. Journal of Affective Disorders, 147, 407-410.
• Schering-Plough (2007). A phase 3, randomized, placebo-controlled, doubleblinded trial evaluating the safety and efficacy of asenapine in subjects continuing lithium or valproic acid/divalproex sodium for the treatment of an acute manic or mixed episode [A7501008]. Available from: http://ichgcp. net/clinical-trials-registry/NCT00145470 [accessed 28 February 2014].
• Selle, V., Schalkwijk, S., Vázquez, G.H., & Baldessarini, R.J. (2014). Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. PharmacoPsychiatry, 47, 43-52.
• Sheehan, D.V., Harnett-Sheehan, K., Hidalgo, R.B., Janavs, J., McElroy, S.L., Amado, D., e.a. (2013). Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. Journal of Affective Disorders, 145, 83-94.
• Sheehan, D.V., McElroy, S.L., Harnett-Sheehan, K., Keck, P.E. Jr., Janavs, J., Rogers, J., e.a. (2009). Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. Journal of Affective Disorders, 115, 376-385.
• Shelton, R.C., & Stahl, S.M. (2004). Risperidone and paroxetine given singly and in combination for bipolar depression. Journal of Clinical Psychiatry, 65, 1715-1719.
• Shi, L., Namjoshi, M.A., Swindle, R., Yu, X., Risser, R., Baker, R.W., e.a. (2004). Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clinical Therapeutics, 26, 125-134.
• Sidor, M.M., & MacQueen, G.M. (2011). Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 72, 156-167.
• Sidor, M.M., & MacQueen, G.M. (2012). An update on antidepressant use in bipolar depression. Current Psychiatry Reports, 14, 696-704.
• Silverstone, T. (2001). Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatrica Scandinavica, 104, 104-109.
• Singh, V., Bowden, C.L., & Mintz, J. (2013). Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania. International Clinical Psychopharmacology, 28, 91-95.
• Smith, A.H., Naylor, G.S., & Moody, J.P. (1978). Placebo-controlled double-blind trial of mianserin hydrochloride. British Journal of Clinical Pharmacology, 5, 67S-70S.
• Speer, A.M., Benson, B.E., Kimbrell, T.K., Wassermann, E.M., Willis, M.W., Herscovitch, P., e.a. (2009). Opposite effects of high and low frequency rTMS on mood in depressed patients: relationship to baseline cerebral activity on PET. Journal of Affective Disorders, 115, 386-394.
• Stamm, T.A. Lewitzka, U., Sauer, C., Pilhatsch, M., Smolka, M.N., Koeberle, U., e.a. (2014). Supraphysiological doses of levothyroxine in bipolar depression: A randomised controlled, double blind study. Journal of Clinical Psychiatry, 75, 162-168.
• Sunovion (2012a). A randomized, 6-week, double-blind, placebo-controlled, fixed-flexible dose, parallel-group study of lurasidone for the treatment of bipolar I depression [D1050236]. 2012a. Available from: https://clinicaltrials.gov/ct2/show/NCT00868959.
• Sunovion (2012b). A randomized, 6-week, double-blind, placebo-controlled, flexible-dose, parallel-group study of lurasidone adjunctive to lithium or divaproex for the treatment of bipolar I depression [D1050235]. Available from: https://clinicaltrials.gov/ct2/show/NCT00868959.
• Suppes, T., Phillips, K.A., & Judd, C.R. (1994). Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biological Psychiatry, 36, 338-340.
• Suppes, T., Datto, C., Minkwitz, M., Nordenhem, A., Walker, C., & Darko, D. (2010). Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders, 121, 106-115.
• Szegedi, A., Calabrese, J.R., Stet, L., MacKle, M., Zhao, J., & Panagides, J. (2012). Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension. Journal of Clinical Psychopharmacology, 32, 46-55.
• Szuba, M.P., Amsterdam, J.D., Fernando, A.T. 3rd, Gary, K.A., Whybrow, P.C., & Winokur, A. (2005). Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. Journal of Clinical Psychopharmacology, 25, 325-330.
• Tamayo, J.M., Sutton, V.K., Mattei, M.A., Diaz, B., Jamal, H.H., Vieta, E., e.a. (2009). Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. Journal of Clinical Psychopharmacology, 29, 358-361.
• Thase, M.E., Jonas, A., Khan, A., Bowden, C.L., Wu, X., McQuade, R.D., e.a. (2008). Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology, 28, 13-20.
• Thase, M.E., Macfadden, W., Weisler, R.H., Chang, W., Paulsson, B., Khan, A., e.a. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology, 26, 600-609.
• Thase, M.E. (2007). BOLDER II study of quetiapine therapy for bipolar depression. Future Neurology, 2, 373-377.
• Tohen, M., Frank, E., Bowden, C.L., Colom, F., Ghaemi, S.N., Yatham, L.N., e.a. (2009). The International Society for Bipolar disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disorders, 11, 453-473.
• Tohen, M., Vieta, E., Calabrese, J., Ketter, T.A., Sachs, G., Bowden, C., e.a. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of general Psychiatry, 60, 1079-1088. Tohen, M., Calabrese, J., Vieta, E., Bowden, C., Gonzalez-Pinto, A., Lin, D., e.a. (2007). Effect of comorbid anxiety on treatment response in bipolar depression. Journal of Affective Disorders, 104, 137-146.
• Tohen, M., McDonnell, D.P., Case, M., Kanba, S., Ha, K., Fang, Y.R., e.a. (2012). Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. British Journal of Psychiatry, 201, 376-382.
• Tohen, M., Katagiri, H., Fujikoshi, S., & Kanba, S. (2013). Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. Journal of Affective Disorders, 149, 196-201.
• Tondo, L., Vazquez, G., & Baldessarini, R. (2010). Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatrica Scandinavica, 121, 404-414.
• Vieta, E., Berk, M., Wang, W., Colom, F., Tohen, M., & Baldessarini, R.J. (2009). Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. Journal of Affective Disorders, 119, 22-27.
• Wang, Z., Gao, K., Kemp, D.E., Chan, P.K., Serrano, M.B., Conroy, C., e.a. (2010). Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. Psychopharmacology Bulletin, 43, 5-21.
• Watson, S., Gallagher, P., Porter, R.J., Smith, M.S., Herron, L.J., Bulmer, S., e.a. (2012). A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biological Psychiatry, 72, 943-949.
• Weisler, R.H., Calabrese, J.R., Thase, M.E., Arvekvist, R., Stening, G., Paulsson, B. e.a. (2008). Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. Journal of Clinical Psychiatry, 69, 769-782.
• Werneke, U. (2009). Complementary medicines in mental health. Evidence-based Mental Health, 12, 1-4.
• Wu, J.C., Kelsoe, J.R., Schachat, C., Bunney, B.G., DeModena, A., Golshan, S., e.a. (2009). Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biological Psychiatry, 66, 298-301.
• Yang, F.D.L. (2009). Optimized therapeutic scheme and individualized dosage of sodium valproate in patients with bipolar sub-type 1. Chinese Journal of New Drugs, 18, 47-52.
• Yong Ning, Z., & Hui, Z. (2005). Therapeutic effect of mirtazapine combined with lithium carbonate on bipolar depression. Chinese Mental Health Journal, 19, 492-494.
• Young, A.H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B.M., & Ferrier, I.N. (2004). Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology, 29, 1538-1545.
• Young, A.M., McElroy, S., Chang, W., Olaulsson, B., Paulsson, B., & Brecher, M. (2008). Placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II). European Neuropsychopharmacology, 18, S371-S372.
• Young, A.H., McElroy, S.L., Bauer, M., Philips, N., Chang, W., Olausson, B. e.a. (2010). A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Journal of Clinical Psychiatry, 71, 150-162.
• Young, A.H., McElroy, S.L., Olausson, B., & Paulsson, B. (2012). A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World Journal of Biological Psychiatry, 15, 96-112.
• Zarate, C.A. Jr., Payne, J.L., Singh, J., Quiroz, J.A., Luckenbaugh, D.A., Denicoff, K.D., e.a. (2004). Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 56, 54-60.
• Zhang, Z.J., Kang, W.H., Tan, Q.R., Li, Q., Gao, C.G., Zhang, F.G., e.a. (2007). Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. Journal of Psychiatric Research, 41, 360-369.
• Zhu, B., Tunis, S.L., Zhao, Z., Baker, R.W., Lage, M.J., Shi, L., e.a. (2005). Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Current Medical Research and Opinion, 21, 555-564.